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of survival functions, used Cox proportional hazard models, and
adjusted standard errors to account for survey design. RESULTS:
The duration of treatment was not different for the 3 interferons
and Copaxone, with 72% of patients continuing with the
therapy after 3 years, while 1.7% of patients on Novantrone
continued treatment after 3 years. Having SPMS increased the
risk of terminating DMA by 67% (p = 0.01) and having moder-
ate disability increased the risk by 77% (p = 0.001) compared
with less advanced disease. Older patients and those with longer
duration of MS were more likely to stay on DMA. Doctor’s
advice was the main reason for starting (47%) or stopping (20%)
DMA therapy, followed by side effects (10% and 27%, respec-
tively), and burden of drug administration (15% and 10%,
respectively). After Avonex, 37% of patients did not take any
DMA for at least 6 months, 17% switched to Copaxone and
15% to Rebif. After Betaseron, 51% stayed off DMAs while
19% switched to Copaxone. 37% of Copaxone users switched to
no DMA, and 16% switched to Avonex. CONCLUSION: The
majority of MS patients continued treatment for three years and
more. Consistent with the risk of cardiotoxicity associated with
long-term use, most patients discontinued Novantrone within
three years.
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OBJECTIVE: Generic substitution of antiepileptic drugs (AEDs)
may be problematic in patients receiving multiple generics
because variability in drug serum concentrations can induce
breakthrough seizures. To investigate clinical consequences of
generic substitution of one versus multiple generics of topiramate
(Topamax®). METHODS: Claims data of Régie de l’assurance-
maladie du Québec (RAMQ) from January 2006-October 2007
were used. Patients with epilepsy (ICD-9 345 or 780.3) treated
with topiramate (Canadian patent expired January 2006) were
selected. An open-cohort person-time design was used to classify
the observation period into mutually exclusive periods of brand,
single-generic, and multiple-generic use. One-year switching
rates of brand-to-generic and switchback-to-brand were com-
puted using Kaplan-Meier methodology. Medical resource utili-
zation (frequency per person–year) was compared among the
three periods using multivariate regressions adjusted for demo-
graphics, treatment characteristics and comorbidities. RESULTS:
A total of 948 patients were observed during 1105 person-years
(p/y) of brand use, 233 p/y of single-generic use, and 92 p/y
of multiple-generic use. Approximately 38% of brand users
switched to generic topiramate, of whom 14% switched back to
brand. Generic users received on average 1.4 generic versions,
with 23% taking two or more versions. Multiple-generic use was
associated with increased utilization of both AEDs and non-AED
drugs compared to brand (RR = 1.27, 95%CI = 1.24; 1.31) and
single-generic use (RR = 1.10, 95%CI = 1.06; 1.13) after covari-
ate adjustment. Multiple-generic use was associated with sig-
niﬁcantly higher hospitalization rate (0.48 vs. 0.83 visit/p/y,
RR = 1.65, 95%CI = 1.28; 2.13) and hospital length of stay (2.6
vs. 3.9 days/p/y, RR = 1.43, 95%CI = 1.27; 1.60), but the effect
was less pronounced in single-generic use (hospitalization:
RR = 1.08, 95%CI = 0.88; 1.34, length of stay: RR = 1.12,
95%CI = 1.03; 1.23). The risk of head injury or fracture was
5 times higher (HR = 5.43, 95%CI = 4.23; 6.97) following a
generic-to-generic switch compared to brand use. CONCLU-
SION: Multiple-generic substitution of topiramate was signiﬁ-
cantly associated with outcomes, such as hospitalizations,
fractures and injuries.
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OBJECTIVE: To examine if pharmacological treatment of
insomnia varied with patient’s gender, ethnic, or both.
METHODS: This was a cross-sectional study using data from
2004 National Ambulatory Medical Care Survey (NAMCS) by
National Center for Health Statistics. We identiﬁed visits at
which at least one frequently used insomnia prescription was
prescribed as deﬁned from the American Insomnia Association.
A series of population-based descriptive analyses were performed
to estimate the national weighted frequency of each drug.
Weighted chi-square statistics were used to compare insomnia
drugs uses by patients with different gender and ethnic charac-
teristics. To provide national estimates, all analyses incorporated
sample weights and standard errors corrections to adjust for the
complex sampling design employed by NAMCS. RESULTS: A
total of 910 million outpatient visits were estimated in the US. in
2004. A total of 24.98 million visits at least one insomnia pre-
scription was prescribed including 3.38 million visits(13.6%)
with FDA approved benzodiazepine receptor agonist; 8.5 million
visits(34.1%) with FDA approved non-benzodiazepine receptor
agonist; and 13.1 million visits (52.4%) with antipsychotic medi-
cations which is used for insomnia treatment without FDA
approved. Female received signiﬁcant more insomnia prescrip-
tion than male (16.4 mil. VS. 8.58 mil., P < 0.0001). Patients
who are Black and Hispanics received less insomnia prescription
than those who are white (P < 0.0001). CONCLUSION: The
study found a signiﬁcant gender and ethnic disparities in the use
of insomnia prescriptions especially to the use of related costly
non-benzodiazepine receptor agonist. The problems of access
barriers to health care for the minority population are still sig-
niﬁcant. The study also provided evidence that the non-FDA
approved prescription medications that were used signiﬁcantly
frequent to treat insomnia than currently approved agents. The
issue of off-label treatment for sleep has been raised concerns
about the adverse effects that develop during the insomnia treat-
ment and limit the efﬁcacy of these medications.
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OBJECTIVE: Since the early 1990s BoNT-A has been used as
prophylaxis treatment for headaches, including migraine. Evi-
dence suggests that this use is primarily in migraine patients who
are refractory to other prophylaxis treatments. This analysis aims
to evaluate the patterns of use and the characteristics of patients
treated with botulinum toxin type A (BoNT-A; BOTOX®; Aller-
gan, Inc, Irvine, CA) for migraine or headache. METHODS: A
retrospective, database claims analysis examining pharmacy and
medical claims from the Source Lx database (WoltersKluwer
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